Zusammenfassung
Die Eiweißbindung von Digitoxin im Plasma ist ausgesprochen hoch und beträgt etwa 97% (Storstein 1977). Das Bindungsprotein für Digitoxin ist wie für die meisten schwach sauren Medikamente das Plasmaalbumin (Storstein 1977).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bowmer, C. J., Lindup, W. E.: Decreased Drug Binding in Uremia: Effect of Indoxyl Sulfate and Other Endogenous Substances on the Binding of Drugs and Dyes to Human Albumin. Biochem Pharmacol 31: 319–323 (1982).
Gibaldi, M., McNamara, P. J.: Apparent Volumes of Distribution and Drug Binding to Plasma Proteins and Tissues. Europ J Clin Pharmacol 13: 373–378 (1978).
Greenblatt, D. J., Sellers, E. M., Koch-Weser, J.: Importance of Protein Binding for the Interpretation of Serum or Plasma Drug Concentrations. J Clin Pharmacol 22: 259–263 (1982).
Holford, N. H. G., Sheiner, L. B.: Understanding the Dose-Effect Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models. Clin Pharmocokin 6: 429–453 (1981).
Kramer, P., Koethe, E., Saul, J., Scheler, F.: Uremic and Normal Plasma Protein Binding of Various Cardiac glydosides under,in vivo’ Conditions. Europ J Clin Invest 4: 53–58 (1974).
Levy, G.: Effect of Plasma Protein Binding of Drugs on Duration and Intensity of Pharmacological Activity. J Pharm Sci 65: 1264–1265 (1976).
Naranjo, C. A., Knouw, V., Sellers, E. M.: Nonfatty Acid-Modulated Variations in Drug Binding Due to Heparin. Clin Pharmacol Therap 31: 746–752 (1982).
Perrier, D., Mayersohn, M., Mercus, F.: Clinical Pharmacokinetics of Digitoxin. Clin Pharmacokin 2: 292–311 (1977).
Peters, U., Grabensee, B., Hausamen, T.-U., Fritsch, W. P., Grosse-Brockhoff, F.: Pharmakokinetik von Digitoxin bei chronischer Niereninsuffizienz. Deutsch Med Wochenschr 102: 109–115 (1977).
Rietbrock, N., Alken, R. G.: Die Therapie der Herzinsuffizienz mit Digitalis. Deutsch Med Wochenschr 105: 1622–1628 (1980).
Storstein, L.: Protein Binding of Cardiac Glycosides in Disease States. Clin Pharmacokinet 2: 220–233 (1977).
Van der Vijgh, W. J. F., Oe PI: Pharmacokinetic Aspects of Digoxin in Patients with Terminal Renal Failure. IV Clinical Implications of Own Observations with a Recent Review ob Literature. Int J Clin Pharmacol 16: 560–564 (1978).
Wilkinson, G. R., Shand, D. G.: A Physiological Approach to Hepatic Drug Clearance. Clin Pharmacol Therap 18: 377–390 (1975).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer Fachmedien Wiesbaden
About this chapter
Cite this chapter
Keller, F., Vöhringer, H.F. (1983). Proteinbindung von Digitoxin. In: Rietbrock, N., Schnieders, B., Schuster, J. (eds) Wandlungen in der Therapie der Herzinsuffizienz. Vieweg+Teubner Verlag, Wiesbaden. https://doi.org/10.1007/978-3-663-19711-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-663-19711-9_11
Publisher Name: Vieweg+Teubner Verlag, Wiesbaden
Print ISBN: 978-3-528-07917-8
Online ISBN: 978-3-663-19711-9
eBook Packages: Springer Book Archive